Astrazeneca Plc $AZN Shares Purchased by Strategic Global Advisors LLC

Strategic Global Advisors LLC lifted its position in Astrazeneca Plc (NYSE:AZN) by 205.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 10,106 shares of the company’s stock after acquiring an additional 6,796 shares during the period. Strategic Global Advisors LLC’s holdings in Astrazeneca were worth $1,774,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Cibc World Market Inc. boosted its stake in shares of Astrazeneca by 21.5% in the third quarter. Cibc World Market Inc. now owns 64,421 shares of the company’s stock worth $4,942,000 after acquiring an additional 11,398 shares during the last quarter. TD Asset Management Inc grew its holdings in Astrazeneca by 20.0% in the 3rd quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock valued at $83,595,000 after buying an additional 181,273 shares in the last quarter. AMG National Trust Bank grew its holdings in Astrazeneca by 20.4% in the 3rd quarter. AMG National Trust Bank now owns 42,983 shares of the company’s stock valued at $3,298,000 after buying an additional 7,289 shares in the last quarter. Assetmark Inc. grew its holdings in Astrazeneca by 6.5% in the 3rd quarter. Assetmark Inc. now owns 310,383 shares of the company’s stock valued at $23,813,000 after buying an additional 19,020 shares in the last quarter. Finally, US Bancorp DE grew its holdings in Astrazeneca by 6.6% in the 3rd quarter. US Bancorp DE now owns 242,181 shares of the company’s stock valued at $18,581,000 after buying an additional 15,065 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Astrazeneca Price Performance

NYSE:AZN opened at $178.79 on Monday. Astrazeneca Plc has a 52 week low of $137.23 and a 52 week high of $212.71. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $277.28 billion, a P/E ratio of 26.85, a P/E/G ratio of 1.55 and a beta of 0.25. The stock’s fifty day moving average is $189.26 and its two-hundred day moving average is $186.07.

Astrazeneca (NYSE:AZN) last posted its earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Equities analysts expect that Astrazeneca Plc will post 9.39 EPS for the current year.

Analyst Ratings Changes

AZN has been the subject of several analyst reports. UBS Group restated a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 9th. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Finally, Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Astrazeneca presently has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.